He goes over the results, and compares and contrasts the therapy's profile to the primary competitor that is currently on the market,...

The data showed a 62% CR/sCR at a median follow-up of 9.5 months. He discusses the patient population, next steps, and the work that...

Rami Elghandour compares Arcellx's estimated 28 month PFS to Carvykti and gives his take on the recent FDA notice about CAR-T.

Chris Heery describes the process relating to bridging therapy that enabled a partial clinical hold to lift.

Arcellx CMO Chris Herry talks about BCMA CAR-T for multiple myeloma at #JPM23.